Resonance Health Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Resonance Health heeft een totaal eigen vermogen van A$10.9M en een totale schuld van A$3.2M, wat de schuld-eigenvermogensverhouding op 29% brengt. De totale activa en totale passiva bedragen respectievelijk A$20.3M en A$9.4M.

Belangrijke informatie

29.0%

Verhouding schuld/eigen vermogen

AU$3.17m

Schuld

Rente dekkingsratio	n/a
Contant	AU$6.85m
Aandelen	AU$10.93m
Totaal verplichtingen	AU$9.35m
Totaal activa	AU$20.28m

Recente financiële gezondheidsupdates

We're Interested To See How Resonance Health (ASX:RHT) Uses Its Cash Hoard To Grow

Mar 12

Resonance Health (ASX:RHT) Is In A Good Position To Deliver On Growth Plans

Aug 19

Recent updates

We're Interested To See How Resonance Health (ASX:RHT) Uses Its Cash Hoard To Grow

Mar 12

Resonance Health (ASX:RHT) Is In A Good Position To Deliver On Growth Plans

Aug 19

Are Robust Financials Driving The Recent Rally In Resonance Health Limited's (ASX:RHT) Stock?

Mar 01

If You Had Bought Resonance Health (ASX:RHT) Stock Three Years Ago, You Could Pocket A 855% Gain Today

Jan 15

How Does Resonance Health's (ASX:RHT) CEO Salary Compare to Peers?

Nov 22

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( A$9.3M ) RHT } overtreffen de korte termijn passiva ( A$6.1M ).

Langlopende schulden: De kortetermijnactiva RHT ( A$9.3M ) overtreffen de langetermijnschulden ( A$3.2M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: RHT heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van RHT is de afgelopen 5 jaar gestegen van 0% naar 29%.

Schuldendekking: De schuld van RHT wordt goed gedekt door de operationele kasstroom ( 43.7% ).

Rentedekking: Er zijn onvoldoende gegevens om te bepalen of de rentebetalingen van RHT op haar schulden goed worden gedekt door EBIT.

Resonance Health Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Belangrijke informatie

Recente financiële gezondheidsupdates

We're Interested To See How Resonance Health (ASX:RHT) Uses Its Cash Hoard To Grow

Resonance Health (ASX:RHT) Is In A Good Position To Deliver On Growth Plans

Recent updates

New major risk - Share price stability

Resonance Health Limited, Annual General Meeting, Nov 28, 2024

Full year 2024 earnings released: EPS: AU$0 (vs AU$0.002 loss in FY 2023)

We're Interested To See How Resonance Health (ASX:RHT) Uses Its Cash Hoard To Grow

New minor risk - Share price stability

New minor risk - Share price stability

Resonance Health Limited, Annual General Meeting, Nov 16, 2023

Resonance Health Ltd Appoints Benjamin Carruthers as Chief Financial Officer, Effective October 2023

Resonance Health Limited Announces Resignation of Liesl Ellies as Joint Company Secretary

Full year 2023 earnings released: AU$0.002 loss per share (vs AU$0.002 loss in FY 2022)

New minor risk - Financial data availability

Resonance Health (ASX:RHT) Is In A Good Position To Deliver On Growth Plans

First half 2023 earnings released: EPS: AU$0 (vs AU$0 in 1H 2022)

Resonance Health Ltd Announces That It Has Lodged Provisional Patent Application in Relation to an Invention for the Detection and Assessment of Fibrosis in the Liver and Other Organ

Insufficient new directors

Resonance Health Limited, Annual General Meeting, Nov 24, 2022

Full year 2022 earnings released: AU$0.002 loss per share (vs AU$0.001 profit in FY 2021)

Full year 2022 earnings released: AU$0.002 loss per share (vs AU$0.001 profit in FY 2021)

FerriScan Now Available on 3 Tesla (3T) MRI Machines

Resonance Health Limited Appoints Liesl Ellies as Joint Company Secretary

Insufficient new directors

Resonance Health Limited Receives United States CPT Code Confirmation for Liversmart

Resonance Health Limited Announces US FDA Clearance for LiverSmart

Resonance Health Ltd Provides Update on its Antisense Oligonucleotide Project for Treating Viral Hepatitis

Resonance Health Limited Announces Filing of Two Patent Applications

Full year 2021 earnings released: EPS AU$0.001 (vs AU$0.002 loss in FY 2020)

Resonance Health Ltd announces R&D Molecular Medicine ASON Project Results of Dosing Study

Full year 2021 earnings released: EPS AU$0.001 (vs AU$0.002 loss in FY 2020)

Chief Executive Officer Alison Laws has left the company

Resonance Health Limited Announces Filing of Patent Application

Resonance Health Limited Provides Update on Its Antisense Oligonucleotide R&D Project for Treating Liver Related Diseases

Are Robust Financials Driving The Recent Rally In Resonance Health Limited's (ASX:RHT) Stock?

Resonance Health Ltd HepaFat-AI Receives CE Marking

Resonance Health Ltd Receives Australian Therapeutic Goods Administration Approval for HepaFat-AI

If You Had Bought Resonance Health (ASX:RHT) Stock Three Years Ago, You Could Pocket A 855% Gain Today

Resonance's HepaFat-AI Incorporated into Blackford Analysis

New 90-day high: AU$0.28

How Does Resonance Health's (ASX:RHT) CEO Salary Compare to Peers?

Resonance Health Ltd Develops New Artificial Intelligence Tool for the Automated Review of Chest Computed Tomography Scans of Patients with Suspected Pulmonary Embolism

Full year earnings released - AU$0.0017 loss per share

Full year earnings released - AU$0.0017 loss per share

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven